Catalyst Pharmaceuticals, Inc. (CPRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.730.00 (0.00%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 5.73 |
| Open | 5.67 |
| Bid | 5.70 x 1100 |
| Ask | 5.82 x 4000 |
| Day's Range | 5.65 - 5.90 |
| 52 Week Range | 2.88 - 5.90 |
| Volume | 5,765,173 |
| Avg. Volume | 1,347,742 |
| Market Cap | 592.276M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | 8.43 |
| EPS (TTM) | 0.68 |
| Earnings Date | Aug 09, 2021 - Aug 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-3% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Simply Wall St.
Did You Miss Catalyst Pharmaceuticals' (NASDAQ:CPRX) Whopping 567% Share Price Gain?
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
- Zacks
Catalyst (CPRX) Up 18.6% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- CNW Group
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced a positive decision in their lawsuit
© 2021 Verizon Media. All rights reserved.
